Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Transplantation. 2011 May 27;91(10):1082-9. doi: 10.1097/TP.0b013e31821457cb.
Preconditioning using lipopolysaccharide (LPS), a Toll-like receptor (TLR)-4 ligand, has been demonstrated to attenuate ischemia-reperfusion injury (IRI) in several organs but has not been sufficiently elucidated in the liver. We investigated the molecular mechanism of protection induced by LPS preconditioning against hepatic IRI.
BALB/c mice underwent 70% hepatic ischemia for 90 min. LPS was injected intraperitoneally 20 hr before ischemia at a range of 1 to 1000 μg/kg. Hepatic injury was evaluated based on serum alanine aminotransferase levels and histopathology. Inflammatory cytokine expression, nuclear factor-κB activation, and c-Jun N-terminal kinase phosphorylation were investigated after reperfusion. Additionally, preischemic expression of negative feedback inhibitors of the TLR4 cascade was examined.
Only the 100 μg/kg LPS pretreatment significantly reduced serum alanine aminotransferase levels and histopathologic damage 6 hr after reperfusion; there was no difference among other LPS concentrations. In mice pretreated with LPS, intrahepatic expression of tumor necrosis factor-α and interleukin (IL)-6 as well as activation of nuclear factor-κB and c-Jun N-terminal kinase were inhibited 1 hr after reperfusion, whereas expression of IL-10, an anti-inflammatory cytokine, was induced. Suppressor of cytokine signaling (SOCS)-1, SOCS-3 and IL-1 receptor-associated kinase-M were upregulated by LPS exposure in the preischemic period.
Hepatic LPS preconditioning elicited the upregulation of specific negative regulators in the TLR4 signaling pathway. Preischemic induction of these regulators plays an important role as immunologic preparation for the subsequent ischemia-reperfusion and produces resistance to liver injury. Preoperative modulation of the TLR4 pathway might become an alternative therapeutic strategy against hepatic IRI.
脂多糖(LPS)作为 Toll 样受体(TLR)-4 的配体,预处理已被证实可减轻几种器官的缺血再灌注损伤(IRI),但在肝脏中尚未得到充分阐明。我们研究了 LPS 预处理诱导的对肝IRI 保护的分子机制。
BALB/c 小鼠进行 70%肝缺血 90 分钟。在缺血前 20 小时,LPS 以 1 至 1000μg/kg 的范围腹腔内注射。根据血清丙氨酸氨基转移酶水平和组织病理学评估肝损伤。在再灌注后研究了炎症细胞因子表达、核因子-κB 激活和 c-Jun N-末端激酶磷酸化。此外,还检查了 TLR4 级联的负反馈抑制剂的预缺血表达。
只有 100μg/kg LPS 预处理可显著降低再灌注后 6 小时的血清丙氨酸氨基转移酶水平和组织病理学损伤;其他 LPS 浓度之间无差异。在 LPS 预处理的小鼠中,再灌注后 1 小时,肿瘤坏死因子-α和白细胞介素(IL)-6 的肝内表达以及核因子-κB 和 c-Jun N-末端激酶的激活受到抑制,而抗炎细胞因子 IL-10 的表达则受到诱导。SOCS-1、SOCS-3 和 IL-1 受体相关激酶-M 在预缺血期间通过 LPS 暴露而上调。
肝 LPS 预处理引起 TLR4 信号通路中特定负调节因子的上调。这些调节剂的预缺血诱导在随后的缺血再灌注中作为免疫准备发挥重要作用,并产生对肝损伤的抵抗力。TLR4 途径的术前调节可能成为治疗肝 IRI 的另一种治疗策略。